What is ZOE?
ZOE operates at the intersection of artificial intelligence and human biology, utilizing large-scale scientific studies to address complex health challenges such as dietary inflammation and metabolic health. By leveraging mobile technology and advanced data analytics, the company provides actionable insights that bridge the gap between clinical research and consumer wellness. Its market position is defined by its ability to translate intricate nutritional data into personalized health recommendations, effectively disrupting traditional wellness paradigms through a rigorous, science-first methodology.
How much funding has ZOE raised?
ZOE has raised a total of $63.2M across 3 funding rounds:
Series A
$10M
Series B
$50.7M
Other Financing Round
$2.5M
Series A (2021): $10M with participation from Softbank and ThirdStream Partners
Series B (2022): $50.7M led by Accomplice, Ahren Innovation Capital, Daphni, and L Catterton
Other Financing Round (2023): $2.5M supported by Steven Bartlett’s Flight Fund
Key Investors in ZOE
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science, providing patient and active capital to visionary entrepreneurs.
Daphni
Daphni is a Paris-based venture capital firm that invests in tech startups with a European focus, emphasizing a human-driven, community-powered approach to fostering long-term change.
L Catterton
L Catterton is a global consumer-focused private equity firm that deploys capital through flagship buyout and growth strategies, leveraging decades of experience in consumer brands worldwide.
What's next for ZOE?
With this major enterprise-level funding, ZOE is poised to scale its operational infrastructure and deepen its investment in proprietary AI models. The strategic roadmap likely involves enhancing the precision of its nutritional diagnostics and broadening its reach into new international markets. As the company transitions from its initial growth phase into a more mature scaling stage, the focus will remain on maintaining the integrity of its longitudinal health studies while optimizing the user experience for its growing global community. The infusion of capital provides the necessary runway to sustain long-term innovation in the competitive health-tech ecosystem.
See full ZOE company page
